Introduction {#S0001}
============

Axillary lymph node tumor burden has a critical impact on the treatment decision and prognosis in patients with breast cancer.[@CIT0001] Therefore, it is important to determine the status of axillary lymph nodes prior to surgery. Usually, patients with clinical positive (cN+) axillary lymph node directly undergo axillary lymph node dissection (ALND). Sentinel lymph node biopsy (SLNB) is the method used to identify axillary lymph node metastasis in patients with cN0 breast cancer who have negative results in axillary imaging or suspected metastasis in axillary imaging, but ultrasound-guided (US-guided) fine needle aspiration (FNA) did not detect cancer cells.[@CIT0002] Positive SLNB results are commonly followed by ALND, which may cause more serious and a greater number of side effects than SLNB alone.[@CIT0003] Patients with negative SLNB results can safely avoid ALND, since the false negative rate (FNR) of SLNB, meaning that SLNB is negative but follow-up ALND finds metastasis in axillary non-sentinel lymph nodes (non-SLN), is no more than 10%,[@CIT0004] which is the clinically acceptable threshold.

Neoadjuvant chemotherapy (NAC) has been increasingly used in patients with operable breast cancer. Following the publication of several prospective multicentric clinical trials evaluating the effectiveness of SLNB in patients with breast cancer who received NAC,[@CIT0005]--[@CIT0007] SLNB has been increasingly performed in the setting of NAC.[@CIT0008],[@CIT0009] However, the reported FNRs varied 0--20% in patients with initial cN0, and 7--30% in patients with initial cN+.[@CIT0010]--[@CIT0015] Furthermore, according to previous reports, metastasis in non-SLNs is not detected in 46--68% of patients with positive SLNs.[@CIT0005]--[@CIT0007] The above data suggest that: 1) SLNB alone may not reliably discriminate patients who could safely avoid further ALND in the setting of NAC; and 2) more than half of the patients have to undergo unnecessary ALND, if the decision is based only on positive SLNB. Therefore, several models have been developed to predict the risk of non-SLN metastasis in patients with breast cancer receiving NAC.[@CIT0016]--[@CIT0018] Unfortunately, these models have limited value with an adjusted area under the receiver operating characteristic curve (AUC) \<0.8. Thus, the development of a new predictive model with excellent discriminatory power is warranted.

Axillary ultrasound (AUS) is a convenient and useful imaging method for clinical axilla staging prior to surgery in breast cancer patients with or without NAC.[@CIT0019]--[@CIT0021] Thus, numerous institutions have adopted AUS as a routine practice to evaluate axillary status prior to surgery in the management of patients with breast cancer. However, to the best of our knowledge, there has been no model including pre-surgery AUS to predict the risk of non-SLN metastasis in patients after NAC. Therefore, this retrospective study aimed to develop such a model in this setting.

Patients and Methods {#S0002}
====================

Patients {#S0002-S2001}
--------

We performed a retrospective review using the digital medical records of patients from January 2013 to January 2018. Patients who met the following criteria were included in the analysis: 1) initial pathological diagnosis of invasive breast cancer; 2) NAC and subsequent mastectomy or breast-conserving surgery; 3) US assessment of the axilla after completing NAC; and 4) SLNB after completing NAC and prior to breast surgery. Patients with distant metastasis and breast cancer combined with other malignancies were excluded. Finally, 298 eligible patients were included in this study. We allocated 228 and 70 patients to the training and testing sets, respectively. The training set was used to evaluate factors affecting the non-SLN status and develop a predictive model. This predictive model was subsequently validated using the testing set.

The information obtained from the physical examination, magnetic resonance imaging, US, and mammography prior to and after NAC was used to determine the tumor size and axilla lymph node metastasis. The clinical T stage was classified according to the 8th American Joint Committee on Cancer, while the clinical tumor response to NAC was classified according to the Response Evaluation Criteria In Solid Tumors guideline (version 1.1). Complete response was defined as complete remission of all known diseases. Partial response was defined as 30% reduction in the maximal diameter of the breast tumor without progression of any lesion or appearance of new disease. Progressive disease was defined as a 20% increase in the maximal diameter and/or the appearance of new lesions. Tumors with change between partial response and progressive disease were classified as stable disease. All included patients underwent FNA before NAC to confirm axilla lymph node metastasis. The expression status of estrogen receptor (ER), progesterone receptor (PR), Ki-67, and human epidermal growth factor receptor 2 (HER2) was determined through immunohistochemical staining. Hormone receptor (HR) positivity was defined as \>1% of cells staining for ER and/or PR. Otherwise, tumors were defined as HR negative. For Ki-67, \<14% and \>14% of tumor cells staining positive denoted low and high expression, respectively. Tumors with HER2 scores of 3+ were considered positive, whereas those with scores of 1+ or 0 were considered negative. In tumors with 2+ scores, fluorescence in situ hybridization was used to determine HER2 amplification. The tumors were classified into four subtypes as follows: luminal A (HR positive, HER2 negative, Ki-67 low expression), luminal B (HR positive, HER2 negative, Ki-67 high expression or HR positive, HER2 positive), HER2 enriched (HR negative, HER2 positive), and basal-like (HR negative, HER2 negative).

US Assessment of Axilla {#S0002-S2002}
-----------------------

The AUS was routinely performed after whole-breast US by a single physician using the Logic E9 (GE Healthcare, Kretz, Zipf, Austria), IU22 (Philips Medical Systems, Bothell, WA, USA), Aixplorer (Supersonic Imaging, Aix-en-Provence, France), Aplio 500 (Toshiba medical system, Japan), or Mylab90 (Esaote, Genoa, Italy) equipped with a 5--14-MHz linear-array transducer.

The results of the AUS were categorized as either positive or negative. AUS was considered positive when an abnormal node with at least one of the following suspicious findings was recorded: diffuse cortical thickening of ≥3 mm; focal cortical bulge; eccentric cortical thickening; rounded hypoechoic node; complete or partial effacement of the fatty hilum; nonhilar cortical blood flow on color Doppler images; complete or partial replacement of the node with an ill-defined or irregular mass; or microcalcifications in the node. Otherwise, the AUS was considered negative.

SLNB Method {#S0002-S2003}
-----------

SLN mapping was conducted using vital blue (1% indigo carmine). Following the injection of 5 mL 1% indigo carmine, the breast was massaged for 5 min. All blue and palpable lymph nodes were excised and submitted as SLNs. The SLNs were initially evaluated through touch imprint cytology. Subsequently, the SLNs were fixed in 10% formalin, embedded in paraffin, and subjected to hematoxylin and eosin staining. The largest metastases in the SLN with a maximal diameter \>2 mm, 0.2--2 mm, and ≤0.2 mm were classified as macrometastases, micrometastases, and isolated tumor cell, respectively. Patients with metastatic SLNs detected using touch imprints routinely underwent immediate ALND during the initial surgery period. Occasionally, patients with tumor-free touch imprints but node-positive permanent sections underwent subsequent ALND, unless they refused to undergo a second surgery.

Evaluation of Non-SLN Metastasis {#S0002-S2004}
--------------------------------

Nodes removed from ALND were submitted as non-SLNs and subjected to histopathologic examination. If any lymph node metastases were detected during ALND, a non-SLN metastasis was considered to exist. Otherwise, the patient was considered free of non-SLN metastasis. For patients who did not undergo ALND, the metastatic status of non-SLNs was defined by means of follow-up imaging information. If lymph nodes were judged as positive at follow-up imaging surveillance with AUS within 6 months and US-guided FNAB reported that metastasis from breast cancer or atypical cells, a non-SLN metastasis was considered to exist. Otherwise, the patient was considered free of non-SLN metastasis.

Statistical Analysis {#S0002-S2005}
--------------------

Quantitative data were expressed as median and range, while qualitative data were presented as frequency and percentage. Univariate analysis was used to identify the risk factors of non-SLN metastasis. Student's *t* test or Mann--Whitney *U*-test was used for the analysis of quantitative data, while the Chi-squared test was employed to analyze qualitative data. All variables with *p*\<0.05 in the univariate analysis were subsequently included in a multivariate analysis. A multivariate logistic regression backward stepwise method was used to develop a model for the prediction of non-SLN metastasis in patients after NAC. Variables with *p*\<0.05 in the multiple analysis were included in the final predictive model. The AUC was calculated to quantify the ability of the model to rank patients according to risk. All tests were two-sided, and *p*\<0.05 indicated statistical significance. The SPSS version 19.0 (IBM Corp., Armonk, NY, USA) software was used for statistical analysis.

Results {#S0003}
=======

Patients\' Characteristics {#S0003-S2001}
--------------------------

The baseline characteristics of patients included in the training set are shown in [Table 1](#T0001){ref-type="table"}. Most patients (219/228) received NAC with an anthracycline- and taxane-based regimen; trastuzumab was added to the regimen for 116 patients with HER2-positive status. Of the 228 patients, 95 patients (41.7%) had breast-conserving surgery after completing NAC, whereas the remaining patients underwent mastectomy. Prior to NAC, 133 patients (58.3%, 133/228) were confirmed as cN+. Post NAC, AUS detected suspicious lymph node metastasis in 21 patients, among whom 17 were classified as cN+ prior to NAC. The SLNB procedure was successfully performed in all patients with at least one lymph node identified. Residual disease was identified in the SLNs (SLN+) of 65 patients (28.5%, 65/228), including 11 and one patients with only micrometastasis and only isolated tumor cell, respectively. ALND was performed in 131 patients (57.5%, 131/228), including 65 SLN+ and 66 SLN− patients. Non-SLN metastasis was found in 48 patients; 13 of these metastases were confined to the non-SLNs. Thus, 13 of the 78 patients with residual nodal disease had a false-negative SLN finding (FNR: 16.7%).Table 1Baseline Characteristics of Patients Included in the Training SetCharacteristicsTotal Number (%)Non-SLN Metastasis (%)*p*NoYesTotal228 (100)180 (78.9)48 (21.1)Age, median (range)48 (25--77)48 (25--76)47 (27--77)0.723Menopause0.402 No112 (49.1)91 (50.6)21 (43.8) Yes116 (50.9)89 (49.4)27 (56.2)Pathological types0.311 IDC214 (93.9)167 (92.8)47 (97.9) Else14 (6.1)13 (7.2)1 (2.1)cT0.130 144 (19.3)36 (20.0)8 (16.7) 2163 (71.5)131 (72.8)32 (66.6) 321 (9.2)13 (7.2)8 (16.7)Pre-NAC cN0.001 Negative95 (41.7)85 (47.2)10 (20.8) Positive133 (58.3)95 (52.8)38 (79.2)ER0.001 Negative114 (50.0)100 (55.6)14 (29.2) Positive114 (50.0)80 (44.4)34 (70.8)PR0.021 Negative142 (62.3)119 (66.1)23 (47.9) Positive86 (37.7)61 (33.9)25 (52.1)HER20.644 Negative112 (49.1)87 (48.3)25 (52.1) Positive116 (50.9)93 (51.7)23 (47.9)Ki-670.044 Low21 (9.2)13 (7.2)8 (16.7) High207 (90.8)167 (92.8)40 (83.3)HR0.008 Negative108 (47.4)94 (52.2)14 (29.2) Positive120 (52.6)86 (47.8)34 (70.8)Molecular type0.019 Luminal A16 (7.0)10 (5.6)6 (12.5) Luminal B104 (45.6)76 (42.2)28 (58.4) HER2+61 (26.8)51 (28.3)10 (20.8) Basal-like47 (20.6)43 (23.9)4 (8.3)Post-NAC AUS\<0.001 Negative207 (90.8)173 (96.1)34 (70.8) Positive21 (9.2)7 (3.9)14 (29.2)cTumor response0.806 CR44 (19.3)35 (19.4)9 (18.8) PR139 (61.0)108 (60.0)31 (64.6) SD and PD45 (19.7)37 (20.6)8 (16.7) SLN number, median (range)3 (1--8)3 (1--8)3 (1--7)\<0.001 SLNM number, median (range)0 (0--5)0 (0--0)1 (0--5)\<0.001[^2]

Univariate Analysis of Factors Predicting the Risk of Non-SLN Metastasis {#S0003-S2002}
------------------------------------------------------------------------

Fifteen factors that could be determined prior to surgery were included in the univariate analysis ([Table 1](#T0001){ref-type="table"}). The results showed that the frequency of non-SLN metastasis was markedly higher in patients with positive lymph nodes than in those with negative findings in post-NAC AUS (66.7% vs 16.4%, *p*\<0.001). In addition, non-SLN metastasis was more likely to be found in patients with a positive node than in those with a negative node prior to NAC (28.6% *vs* 10.5%, *p*=0.001), and in patients with positive ER and PR than in those with negative ER and PR (29.8% vs 12.3%, *p*=0.001 for ER; 29.1% vs 16.2%, *p*=0.021 for PR). Low expression of Ki-67 was linked to more non-SLN metastasis (38.1% vs 19.3%, *p*=0.044). However, the risk of non-SLN metastasis did not exhibit a significant relationship with the expression of HER2 (*p*=0.644). Therefore, the common molecular subtype which takes into account the expression of ER and PR, as well as HER2 and Ki-67 was not included in the analysis. Instead, the factor HR, which classified patients according to the expression of ER and PR, was included. Expectedly, patients with positive HR were at a higher risk of having non-SLN metastasis than those with negative HR (28.3% vs 13.0%, *p*=0.004). Fewer SLNs and more SLNMs were associated with an increased likelihood of detecting residual disease in non-SLNs (*p*\<0.001 for SLN number, *p*\<0.001 for SLNM number). However, the risk of non-SLN metastasis was not correlated with age (*p*=0.723), menopause status (*p*=0.402), pathological type (*p*=0.311), clinical T stage (*p*=0.130), and clinical tumor response (*p*=0.806).

Multivariate Analysis of Factors Predicting the Risk of Non-SLN Metastasis {#S0003-S2003}
--------------------------------------------------------------------------

Five factors with *p*\<0.05 in the univariate analysis, namely nodal status prior to NAC, status of post-NAC AUS, HR expression, SLN number, and SLNM number were included in the multivariate analysis with the logistic regression backward stepwise method. The results showed that nodal status prior to NAC (odds ratio \[OR\]: 2.867, 95% confidence interval \[CI\]: 1.198--6.862, *p*=0.018), post-NAC AUS status (OR: 4.933, 95% CI: 1.605--15.128, *p*=0.005), SLN number (OR: 0.514, 95% CI: 0.365--0.723, *p*\<0.001), and SLNM number (OR: 2.800, 95% CI: 1.751--4.478, *p*\<0.001) were independent predictors of non-SLN metastases ([Table 2](#T0002){ref-type="table"}). Of note, HR expression (*p*=0.516) was not identified as an independent predictor of non-SLN metastases.Table 2Multiple Analysis of Factors Predicting the Risk of Non-SLN MetastasisFactorsBSEWaldOR (95% CI)*p*Pre-NAC cN1.0530.4455.5992.867 (1.198--6.862)0.018Post-NAC AUS1.5960.5727.7944.933 (1.609--15.128)0.005SLN number−0.6660.17514.5520.514 (0.365--0.723)\<0.001SLNM number1.0300.24018.4782.800 (1.751--4.478)\<0.001[^3]

Predictive Model and Its Validation {#S0003-S2004}
-----------------------------------

A model predicting the risk of non-SLN metastasis in patients with breast cancer receiving NAC was developed using variables with *p*-values \<0.05 in the multivariate analysis as follows, with *P* denoting the probability of non-SLN metastases: $$\documentclass[12pt]{minimal}
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in which *a* indicated nodal status prior to NAC, *b* indicated the results of post-NAC AUS, *c* indicated the SLN number, and *d* indicated the SLNM number. The AUC for the model was 0.838 (95% CI: 0.774--0.902, *p*\<0.001), suggesting excellent discrimination ([Figure 1](#F0001){ref-type="fig"}).Figure 1Receiver operating curve for the training set. The area under the curve was 0.838 (95% CI: 0.774--0.902, *p*\<0.001).

The baseline characteristics of patients (n=70) included in the testing set were comparable with those of patients assigned to the training set ([[Supplementary Table S1](https://www.dovepress.com/get_supplementary_file.php?f=239921.docx)]{.ul}). ALND was performed in 40 patients (57.1%, 40/70), including 18 SLN+ and 22 SLN− patients. Non-SLN metastasis was found in nine patients; three of these were confined to the non-SLNs. The above predictive model was applied to the testing set for internal validation, yielding an AUC of 0.808 (95% CI: 0.609--1.000, *p*=0.003, [Figure 2](#F0002){ref-type="fig"}), thus demonstrating excellent discriminatory power. With a 30% cutoff value for predicted probability, this model had a sensitivity of 77.8%, specificity of 96.4%, accuracy of 87.1%, negative predictive value of 96.4%, positive predictive value of 50.0%, and FNR of 12.5% (2/16).Figure 2Receiver operating curve for the testing set. The area under the curve was 0.808 (95% CI: 0.609--1.000, *p*=0.003).

Discussion {#S0004}
==========

Initially, there was concern regarding the unacceptably high FNR for SLNB after NAC on account of fibrosis in lymphatic channels changing lymphatic drainage in the breast and nonuniform response to treatment in the axillary nodes. Based on this concern, ALND was previously the standard treatment for patients with breast cancer after NAC. However, ALND is associated with considerable morbidity that seriously affects the life quality of patients. Several prospective multicenter clinical trials were performed to evaluate the effectiveness of SLNB in patients with breast cancer receiving NAC. In recent years, SLNB has been increasingly used in the treatment of patients with breast cancer after NAC, aiming to minimize the extent of axillary surgery. Several methods have been developed to decrease the FNRs for SLNB after NAC, such as removing pre-NAC clipped node during SLNB,[@CIT0022],[@CIT0023] or performing SLNB only in patients with normal axilla detected through post-NAC AUS.[@CIT0024] While these researches had placed great value on the FNRs, a large majority of patients with positive SLNs, but without metastasis in non-SLNs, had to undergo unnecessary ALND. Furthermore, the results of the Z0011[@CIT0025] and IBCSG 23--01[@CIT0026] trials indicated that patients with limited positive SLNs appear to have no survival benefit from ALND. Therefore, a predictive model such as the one developed in the present study to discriminate patients with or without metastasis in non-SLNs is of clinical significance.

Although previous studies suggested that pathological T stage, lymphovascular invasion, or extracapsular extension were significantly associated with the metastasis of non-SLNs,[@CIT0017],[@CIT0018] we excluded these from the analysis of this study as they could not be determined prior to breast surgery. In our medical center, all patients with breast cancer undergo preoperative AUS owing to its convenience and specificity. Several previous studies showed that a positive result on AUS indicated more extensive axillary nodal metastasis.[@CIT0027]--[@CIT0030] Kim et al reported that preoperative AUS could predict the risk of non-SLN metastasis and facilitate the selection of patients with early breast cancer in whom ALND could be omitted.[@CIT0031] It was also reported that the US could identify residual nodal disease after NAC with clearly defined standards.[@CIT0020] Thus, the US has been considered the most convenient and economic noninvasive method to evaluate the axilla, though it was not superior to other methods for the assessment of primary tumor response to NAC.[@CIT0032] Therefore, we added the post-NAC AUS status in the analysis of our study and demonstrated that it was the most significant predictor of non-SLN metastasis (OR: 4.933, *p*=0.005).

In addition to the post-NAC AUS status, the results of the multivariate analysis performed in this study showed that three other factors (i.e., nodal status prior to NAC, SLN number, and SLNM number) were the independent factors predicting the risk of non-SLN metastasis in patients with breast cancer after NAC. Indeed, both a positive axillary lymph node at presentation and greater SLNM number indicated heavier axillary burden. And the more SLNs were removed, the less likely metastasis would be identified in the rest of lymph nodes. Similarly, numerous previous studies have demonstrated the significant association between SLNM number and non-SLN metastasis.[@CIT0017],[@CIT0018],[@CIT0033] Furthermore, some clinical trials have reported a significant decrease in the FNRs with an increasing number of resected SLNs.[@CIT0005],[@CIT0014] Thus, nodal status prior to NAC and SLNM number were identified as the risk factors of non-SLN metastasis (OR: 2.867, *p*=0.018 for nodal status prior to NAC, OR: 2.800, *p*\<0.001 for SLNM number), while SLN number was identified as the protective factor of non-SLN metastasis (OR: 0.514, *p*\<0.001).

Several models have been introduced in previous studies.[@CIT0016]--[@CIT0018] However, these models included factors that could only be determined after breast surgery, such as pathological T stage, lymphovascular invasion, and extracapsular extension. Thus, they could not be used to facilitate the selection of patients who could avoid unnecessary ALND. In addition, these models had relatively limited discriminatory power with AUCs \<0.8. Therefore, based on the results of the multivariate analysis conducted in this study, we developed a simple predictive model by including four significant factors that could be determined prior to breast surgery and yielded an AUC of 0.838 in the training set. The best cutoff of predicted probability according to the maximal Youden's index criteria was 30% for this model to discriminate patients who could avoid unnecessary ALND. This model was subsequently validated in an internal testing set and an AUC of 0.808 was achieved, demonstrating the reliable discriminatory power of this model.

There were several limitations to our study. Firstly, the SLNB method is correlated with the detection of SLNs.[@CIT0034] In our study, SLN mapping in all patients was conducted using only vital blue, which performs poorly in the identification of SLNs compared with radiolabeled colloid alone or blue dye.[@CIT0034] However, SLNB was successfully conducted in all patients in this study with at least one SLN removed. At least three SLNs were removed in 69.3% and 68.6% of patients in the training set and testing set, respectively, suggesting that the SLNB method was reliable in our center. Secondly, we validated this model internally. It requires further validation in patients from other centers before it can be widely used in the clinical setting. Thirdly, a proportion of the patients did not undergo ALND to obtain definitive pathological results of non-SLN. For these patients, we have to rely on follow-up imaging examination and US-guided FNA to evaluate the status of non-SLN. Finally, this was a single-center retrospective study, which inevitably leads to bias in the selection of patients. Additional multicenter prospective studies are warranted to verify the present results.

Conclusion {#S0005}
==========

A new and simple model was developed to predict non-SLN metastasis in invasive breast cancer after NAC. It incorporated post-NAC AUS with other factors that could be determined prior to breast surgery. Thus, it was able to facilitate the selection of patients in whom unnecessary ALND could be omitted. This model performed excellently in the internal validation with an AUC of 0.808. However, it requires external validation in patients from other centers before it can be widely utilized in the clinical setting.
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